BioSenic SA
Develops therapies for autoimmune diseases, inflammation, and bone disorders.
BIOS | BR
Overview
Corporate Details
- ISIN(s):
- BE0970179827 (+1 more)
- LEI:
- 549300HFIIMTOP1DFR76
- Country:
- Belgium
- Address:
- RUE GRANBONPRÉ 11, 1435 MONT-ST-GUIBERT
- Website:
- http://www.biosenic.com/
Description
BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2020-12-11 08:00 |
Bone Therapeutics announces pricing of private placement
|
English | PDF • 55.8 KB | ||
| 2020-12-11 08:00 |
Bone Therapeutics réalise un placement privé
|
French | PDF • 62.0 KB | ||
| 2020-11-16 07:00 |
Bone Therapeutics announces completion of the acquisition of its cell therapy m…
|
English | PDF • 188.8 KB | ||
| 2020-11-16 07:00 |
Finalisation de l’acquisition de SCTS, la filiale de production de thérapie cel…
|
French | PDF • 234.6 KB | ||
| 2020-11-10 07:00 |
Bone Therapeutics and its collaborators awarded €3 million in funding under the…
|
English | PDF • 194.2 KB | ||
| 2020-11-10 07:00 |
Bone Therapeutics et ses partenaires reçoivent un financement de 3M€ via BioWin…
|
French | PDF • 242.5 KB | ||
| 2020-10-30 07:00 |
PR_2020-10-30_BOTHE_2020-Q3_EN_Final.pdf
|
English | PDF • 210.9 KB | ||
| 2020-10-30 07:00 |
PR_2020-10-30_BOTHE_2020-Q3_FR_Final.pdf
|
French | PDF • 260.0 KB | ||
| 2020-10-29 07:00 |
Bone Therapeutics and Catalent sign agreements to streamline production of the …
|
English | PDF • 196.3 KB | ||
| 2020-10-29 07:00 |
Bone Therapeutics signe des accords avec Catalent pour optimiser la production…
|
French | PDF • 242.6 KB | ||
| 2020-10-23 07:00 |
SRIW_BONE THERAPEUTICS_TR-1_2020-10-16.pdf
|
French | PDF • 628.8 KB | ||
| 2020-10-23 07:00 |
PR_2020-10-23_BOTHE_CB Denominator_EN_Final.pdf
|
English | PDF • 191.6 KB | ||
| 2020-10-23 07:00 |
PR_2020-10-23_BOTHE_CB Denominator_FR_Final.pdf
|
French | PDF • 242.9 KB | ||
| 2020-10-20 07:00 |
Bone Therapeutics reaches 50% treated patients in ongoing JTA-004 Phase III piv…
|
English | PDF • 186.7 KB | ||
| 2020-10-20 07:00 |
Bone Therapeutics a traité 50% des patients dans son étude pivot de Phase III é…
|
French | PDF • 234.4 KB |
Automate Your Workflow. Get a real-time feed of all BioSenic SA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioSenic SA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioSenic SA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-08-16 | Rieger Francois | Board | Sell | 2,500,000 | 25,000.00 EUR |
| 2024-08-06 | Rieger Francois | Board | Sell | 868,653 | 7,186.87 EUR |
| 2024-08-05 | POMI SCHNEITER VERONIQUE | Board | Sell | 534,750 | 4,331.47 EUR |
| 2024-08-02 | POMI SCHNEITER VERONIQUE | Board | Sell | 193,900 | 1,609.37 EUR |
| 2024-08-01 | Rieger Francois | Board | Sell | 1,236,684 | 11,463.87 EUR |
| 2024-08-01 | POMI SCHNEITER VERONIQUE | Board | Sell | 140,003 | 1,246.03 EUR |
| 2024-07-31 | POMI SCHNEITER VERONIQUE | Board | Sell | 503,771 | 4,685.07 EUR |
| 2024-07-30 | POMI SCHNEITER VERONIQUE | Board | Sell | 360,021 | 3,348.20 EUR |
| 2024-07-29 | POMI SCHNEITER VERONIQUE | Board | Sell | 372,893 | 3,430.62 EUR |
| 2024-07-24 | POMI SCHNEITER VERONIQUE | Board | Sell | 2,168,361 | 21,033.10 EUR |
Peer Companies
